Monte Rosa Therapeutics Stock Performance
| GLUE Stock | USD 5.62 0.21 3.60% |
The company secures a Beta (Market Risk) of 1.14, which conveys a somewhat significant risk relative to the market. Monte Rosa returns are very sensitive to returns on the market. As the market goes up or down, Monte Rosa is expected to follow. At this point, Monte Rosa Therapeutics has a negative expected return of -0.25%. Please make sure to verify Monte Rosa's maximum drawdown, as well as the relationship between the daily balance of power and price action indicator , to decide if Monte Rosa Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Monte Rosa Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.52 | Five Day Return (9.75) | Year To Date Return (18.00) | Ten Year Return (72.47) | All Time Return (72.47) |
1 | Acquisition by Sharon Townson of 36000 shares of Monte Rosa subject to Rule 16b-3 | 01/02/2025 |
2 | Monte Rosa Therapeutics Is In A Good Position To Deliver On Growth Plans | 01/31/2025 |
3 | BlackRock, Inc. Increases Stake in Monte Rosa Therapeutics Inc | 02/04/2025 |
4 | Avoro Capital Advisors LLC Reduces Stake in Monte Rosa Therapeutics Inc | 02/14/2025 |
5 | Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference | 02/24/2025 |
6 | Molecular Glues Competitive Landscape 2025 Exploring 65 Drugs and 50 Biotech Players in the Molecular Glue Space | 03/06/2025 |
7 | Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year ... | 03/11/2025 |
8 | Disposition of 541897 shares by Versant Venture Capital Vi, L.p. of Monte Rosa at 6.0 subject to Rule 16b-3 | 03/14/2025 |
9 | Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 ... | 03/20/2025 |
| Begin Period Cash Flow | 132.7 M |
Monte |
Monte Rosa Relative Risk vs. Return Landscape
If you would invest 722.00 in Monte Rosa Therapeutics on December 25, 2024 and sell it today you would lose (139.00) from holding Monte Rosa Therapeutics or give up 19.25% of portfolio value over 90 days. Monte Rosa Therapeutics is currently does not generate positive expected returns and assumes 4.778% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Monte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Monte Rosa Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Monte Rosa's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Monte Rosa Therapeutics, and traders can use it to determine the average amount a Monte Rosa's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0517
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GLUE |
Estimated Market Risk
| 4.78 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Monte Rosa is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Monte Rosa by adding Monte Rosa to a well-diversified portfolio.
Monte Rosa Fundamentals Growth
Monte Stock prices reflect investors' perceptions of the future prospects and financial health of Monte Rosa, and Monte Rosa fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Monte Stock performance.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 29.17 M | ||||
| Shares Outstanding | 61.51 M | ||||
| Price To Earning | 1.91 X | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 4.74 X | ||||
| Revenue | 75.62 M | ||||
| Gross Profit | (37.24 M) | ||||
| EBITDA | (81.11 M) | ||||
| Net Income | (72.7 M) | ||||
| Cash And Equivalents | 294.14 M | ||||
| Cash Per Share | 6.32 X | ||||
| Total Debt | 42.72 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 20.11 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | 42 M | ||||
| Earnings Per Share | (0.98) X | ||||
| Market Capitalization | 358.6 M | ||||
| Total Asset | 438.73 M | ||||
| Retained Earnings | (438.59 M) | ||||
| Working Capital | 220.49 M | ||||
About Monte Rosa Performance
By analyzing Monte Rosa's fundamental ratios, stakeholders can gain valuable insights into Monte Rosa's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Monte Rosa has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Monte Rosa has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 36.85 | 32.75 | |
| Return On Tangible Assets | (0.17) | (0.17) | |
| Return On Capital Employed | (0.29) | (0.30) | |
| Return On Assets | (0.17) | (0.17) | |
| Return On Equity | (0.33) | (0.31) |
Things to note about Monte Rosa Therapeutics performance evaluation
Checking the ongoing alerts about Monte Rosa for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Monte Rosa Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Monte Rosa generated a negative expected return over the last 90 days | |
| Monte Rosa has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 75.62 M. Net Loss for the year was (72.7 M) with loss before overhead, payroll, taxes, and interest of (37.24 M). | |
| Monte Rosa has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs |
- Analyzing Monte Rosa's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Monte Rosa's stock is overvalued or undervalued compared to its peers.
- Examining Monte Rosa's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Monte Rosa's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Monte Rosa's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Monte Rosa's stock. These opinions can provide insight into Monte Rosa's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Monte Stock analysis
When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |